论文部分内容阅读
目的:探讨长效及普通干扰素治疗慢性丙型肝炎临床疗效及停药后持续应答。方法:选取2012-2013年我院收治的70例慢性丙型肝炎患者为研究对象,其中长效干扰素组采用聚乙二醇干扰素α-2a、α-2b(PEG-INFα-2a、PEG-INFα-2b)联合利巴韦林进行抗病毒治疗(n=40例),普通干扰素组采用普通IFNα-2a联合利巴韦林治疗(n=30例),均分别于治疗4、12、24、48w及治疗结束后24w、144w评价疗效,收集相关的基础资料,回访患者治疗后持续应答情况。结果:长效干扰素组持续病毒学应答率(SVR)为94.8%,显著高于普通干扰素组的81.3%(P<0.01);治疗后停药观察144w长效干扰素组持续应答率为78%,显著高于普通干扰素组36.7%(P<0.01)。结论:长效干扰素联合利巴韦林治疗方案疗效显著优于普通干扰素联合利巴韦林,治疗后停药144w观察复发率明显低于普通干扰素组。
Objective: To investigate the clinical efficacy of long-acting and ordinary interferon in the treatment of chronic hepatitis C and the sustained response after discontinuation. Methods: Seventy patients with chronic hepatitis C who were treated in our hospital from 2012 to 2013 were selected as the study subjects. Peginterferon α-2a and α-2b (PEG-INFα-2a, PEG -INFα-2b) combined with ribavirin (n = 40). The common interferon group was treated with normal IFNα-2a and ribavirin (n = 30) , 24,48w and 24w, 144w after the end of treatment to evaluate the curative effect, collect the related basic data, and visit the patient’s response to the continuous response after treatment. Results: The sustained virological response rate (SVR) of the long-acting interferon group was 94.8%, significantly higher than that of the normal interferon group (81.3%, P <0.01). After discontinuation of treatment, the sustained response rate of the 144-w long interferon group was 78%, significantly higher than 36.7% of normal interferon group (P <0.01). Conclusion: The efficacy of long-acting interferon plus ribavirin is significantly better than that of common interferon and ribavirin. The relapse rate of 144-w withdrawal after treatment is obviously lower than that of normal interferon.